Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...

Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...

Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...